Cognitive Training and Neuroplasticity in Mild Cognitive Impairment: COGIT-2 Trial
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age55-89
SponsorColumbia University
About this trial
Effective, clinically meaningful treatments are lacking for patients with mild cognitive impairment (MCI), which is associated with increased risk of transition to dementia. Cognitive training represents an important therapeutic strategy. In a previous study, crossword puzzles were found to be superior to computerized cognitive training on the primary cognitive outcome and function with decreased brain atrophy. Building on these findings, this study will evaluate and compare the impact of high dose crosswords (4 puzzles per week) to low dose crosswords (1 puzzle per week) and a health education control group on the cognition and function of participants.
Eligibility criteria
Qualifiers
Access to a home desktop or laptop computer or tablet at acceptable internet speed for the study duration.
Participants need to be 55 to 89 years of age (inclusive) at the time of informed consent.
Females need to be post-menopausal (last period more than 12 months earlier by history).
Subjective cognitive complaints, i.e., memory or other cognitive complaints, e.g., naming/language.
Disqualifiers
Diagnosis of dementia of any type.
Current clinical diagnosis of schizophrenia, schizoaffective disorder, psychosis, or bipolar I disorder (Diagnostic and Statistical Manual of Mental Disorders (DSM-5 TR) criteria).
Current unstable or untreated major depression, or active suicidality based on a Suicide Severity Rating Scale (C-SSRS Screen version: positive answer to question 1 or 2 followed by item 6 positive answer leads to exclusion. Negative answer to questions 1 and 2: interview ends and the participant is not excluded for active suicidality).
Current or recent (past 6 months) alcohol or substance use disorder (DSM-5 TR criteria).
Trial design
Treatments tested in this trial
- Cognitive Training
Treatment groups
240 Participants
are divided into 3 treatment groupsSponsors and collaborators
Columbia University
Lead sponsor
National Institute on Aging (NIA)
Collaborator
Source ClinicalTrials.gov